Morphosys Group Ag Anticipates Close Of Proposed Acquisition By Novartis In H1 2024, Submit A New Drug Application For Pelabresib In Combination With Ruxolitinib In Myelofibrosis To FDA And Marketing Authorization Application To European Medicines Agency In H2 2024
Morphosys Group Ag預計將在2024年上半年完成諾華的擬議收購,向美國食品藥品管理局提交Pelabresib與魯索利替尼聯合治療骨髓纖維化的新藥申請,並於2024年下半年向歐洲藥品管理局提交上市許可申請